Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 15/20 | 1.00 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.62 |
| ▸ | CPA1 | P15085 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5147971 | 0.99 | CPB1 (0.98) | CPB1CPB2CPA1 | |
| SCHEMBL31061076 | 0.91 | CPB1 (1.00) | CPB1CPB2CPA1 | |
| SCHEMBL4947561 | 0.91 | CPB1 (1.00) | CPB1CPB2CPA1 | |
| SCHEMBL4942017 | 0.90 | CPB1 (1.00) | CPB1CPB2CPA1 | |
| SCHEMBL4537473 | 0.90 | CPB1 (1.00) | CPB1CPB2CPA1 | |
| Water SCHEMBL16240480 | 0.89 | CPB1 (0.98) | CPB1CPB2CPA1 | |
| Hydrochloric Acid SCHEMBL5470806 | 0.89 | CPB1 (0.98) | CPB1CPB2CPA1 | |
| SCHEMBL16210645 | 0.89 | CPB1 (0.98) | CPB1CPB2CPA1 | |
| Water SCHEMBL14977064 | 0.89 | CPB1 (0.98) | CPB1CPB2CPA1 | |
| Water SCHEMBL16241881 | 0.89 | CPB1 (0.98) | CPB1CPB2CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1864979-A1 | Imidazole-derivatives as TAFAIa-inhibitors | Sanofi-Aventis Deutschland GmbH (DE) | 2007-12-12 | — | — | EP | claimed |
| US-20070129341-A1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-07 | — | — | US | claimed |
| EP-1740569-A1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | claimed |
| WO-2005105781-A1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-11-10 | — | — | WO | claimed |
| US-8710232-B2 | Imidazole derivatives used as TAFIa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| EP-1864979-A1 | Imidazole-derivatives as TAFAIa-inhibitors | Sanofi-Aventis Deutschland GmbH (DE) | 2007-12-12 | — | — | EP | disclosed |
| US-20070129341-A1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-07 | — | — | US | disclosed |
| EP-1740569-A1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105781-A1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129341-A1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | TFPI, TFPI2, SERPINC1 | CPB1 67/4885CPB2 49/4885CPA1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.